Taro Pharmaceutical EPS beats by $0.25, beats on revenue

  • Taro Pharmaceutical (NYSE:TARO): Q2 Non-GAAP EPS of $1.09 beats by $0.25; GAAP EPS of -$0.50 misses by $1.34.
  • Revenue of $147.1M (+25.1% Y/Y) beats by $9.87M.
  • Settlements and loss contingencies of $60.0 million reflect an additional legal contingency provision related to ongoing multi-jurisdiction civil antitrust matters.
  • Press Release

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.